Limosilactobacillus reuteri SLZX19-12 Protects the Colon from Infection by Enhancing Stability of the Gut Microbiota and Barrier Integrity and Reducing Inflammation

Jianmin Wu, Zishen Lin, Xian Wang, Ying Zhao, Jinbiao Zhao, Hu Liu, Lee J. Johnston, Lin Lu, Xi Ma

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Limosilactobacillus reuteri plays an important role in regulating intestinal functions and maintaining barrier integrity in animals. In this study, Limosilactobacillus reuteri strain SLZX19-12 was isolated from the fecal microbiota of Tibetan pigs, and it was found that this strain is sensitive to common antibiotics and has strong resistance to stress. Upon being administered by gavage at different doses, including low, medium, and high doses, for 14 days, Limosilactobacillus reuteri SLZX19-12 may enhance the intestinal barrier. After administration of a high dose of SLZX19-12, mice were challenged with Salmonella enterica serovar Typhimurium SL1344. Infection with Salmonella Typhimurium SL1344 led to disordered colonic microbiotas, colonic inflammation through the S100A8/S100A9-NF-κB pathway and potential apoptosis, and translocation of pathogens to parenteral visceral organs in mice. However, the mice pretreated with Limosilactobacillus reuteri SLZX19-12 showed lower loads of Salmonella in visceral organs, less colonic inflammation, and higher barrier integrity. More importantly, the administration of strain SLZX19-12 resulted in a more stable microbiota structure of the colon, in which the abundance of Alloprevotella was greatly enhanced. Therefore, this study suggests that Limosilactobacillus reuteri SLZX19-12 can protect the colon from infection by enhancing the stability of gut microbiota and barrier integrity and reducing inflammation. IMPORTANCE The use of antibiotics to treat bacterial infections leads to a series of side effects. As an alternative method, the biocontrol strategy, which uses probiotics to suppress pathogens, is considered a potential way to deal with bacterial infections in gut. However, there are few probiotics that are currently safe and can protect against infection. In this study, Limosilactobacillus reuteri strain SLZX19-12 was obtained from Tibetan pigs, which have higher resistance to infection. This strain is sensitive to conventional antibiotics, secretes a wide spectrum of enzymes, and also promotes the intestinal barrier function in mice. In addition, Limosilactobacillus reuteri SLZX19-12 can promote the stability of the gut microbiota to avoid or alleviate the occurrence or development of foodborne infections.

Original languageEnglish (US)
JournalMicrobiology Spectrum
Issue number3
StatePublished - Jun 2022

Bibliographical note

Funding Information:
This work was supported by the National Natural Science Foundation of China (31930106 and 31829004), the National Ten-thousand Talents Program of China (23070201), the Henan Province Public Benefit Research Foundation (201300111200-05), the 2115 Talent Development Program of China Agricultural University (1041-00109019), and the 111 Project (B16044). We declare no conflict of interest.

Publisher Copyright:
Copyright © 2022 Wu et al.


  • Lactobacillus reuteri
  • Limosilactobacillus reuteri
  • Salmonella Typhimurium SL1344
  • Tibetan piglets
  • colon
  • gut microbiota
  • host defense
  • infection
  • Probiotics/therapeutic use
  • Colon/microbiology
  • Gastrointestinal Microbiome
  • Inflammation
  • Anti-Bacterial Agents/pharmacology
  • Salmonella typhimurium
  • Animals
  • Swine
  • Mice

PubMed: MeSH publication types

  • Research Support, Non-U.S. Gov't
  • Journal Article


Dive into the research topics of 'Limosilactobacillus reuteri SLZX19-12 Protects the Colon from Infection by Enhancing Stability of the Gut Microbiota and Barrier Integrity and Reducing Inflammation'. Together they form a unique fingerprint.

Cite this